The role of intravenous iron in anemia management and transfusion avoidance. (terbuka di window baru)

Auerbach M, Goodnough LT, Picard D, Maniatis A.

Sumber‎: Transfusion 2008;48(5):988-1000.

Index‎: PubMed 18346021

DOI‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 (terbuka di window baru)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (terbuka di window baru)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Sumber‎: BJU Int 2011;108(10):1582-7.

Index‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (terbuka di window baru)

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. (terbuka di window baru)

Lepor H, Lipkin M, Slova D.

Sumber‎: Urology 2010;75(6):1424-8.

Index‎: PubMed 20513505

DOI‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 (terbuka di window baru)

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. (terbuka di window baru)

Nieder AM, Rosenblum N, Lepor H.

Sumber‎: Urology 2001;57(4):737-41.

Index‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 (terbuka di window baru)